Pilot Study to Determine Safety and Efficacy of Orbital Injections of LIPO-102 in Patients With Symptomatic Exophthalmos Associated With Thyroid-related Eye Disease (TED)
NCT ID: NCT00954057
Last Updated: 2015-03-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
11 participants
INTERVENTIONAL
2009-09-30
2011-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Lanreotide (Somatuline Autogel) in Thyroid-associated Ophthalmopathy Treatment
NCT00288522
Triamcinolone Acetonide Injections to Treat Diabetic Macular Edema
NCT00231023
Everads Injector in Suprachoroidal Administration of TA Suspension, for Treatment of Patients With DME
NCT06314217
Study of EYP-1901 in Patients With Nonproliferative Diabetic Retinopathy (NPDR)
NCT05383209
The Therapeutic Effect of Dysthyroid Optic Neuropathy
NCT04096612
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
LIPO-102
Intraorbital Injection
LIPO-102
intraorbital injection
Placebo
Intraorbital Injection
Placebo
intraorbital injection
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
LIPO-102
intraorbital injection
Placebo
intraorbital injection
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Symptomatic exophthalmos
* Inactive Thyroid Eye Disease
* Signed informed consent
Exclusion Criteria
* Treatment with an investigational agent within 30 days of first dose
* History of Thyroid Eye Disease less than 6 months
* Previous decompression surgery
* Glaucoma
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Neothetics, Inc
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Adelaide, , Australia
Brisbane, , Australia
Melbourne, , Australia
Sydney, , Australia
Auckland, , New Zealand
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LIPO-102-CL-06
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.